ClinicalTrials.gg
RecruitingNCT06308406Updated Apr 11, 2024

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

A Phase 1/2 interventional study of Bevacizumab; HRS-1167 in Recurrent Ovarian Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 18 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 6 open to participants now, 6 under way, 4 of them phase 3. Ovarian Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
14th of 16
54 · median 188
Started
2024
with 3 others
Phase 1/2
2 of 16
2 open now
Registered
12th of 16
by date

Among the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 14th largest by planned enrollment, is one of 4 that started in 2024, is one of 2 in phase 1/2, and was the 12th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study is a multicenter, open-label Phase Ib/II clinical trial to observe and evaluate the safety, tolerability and pharmacokinetics of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer mechanical characterization and preliminary evaluation of the efficacy of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer.

03

Conditions studied

  • Recurrent Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily join this study, sign the form, have good compliance, and be able to cooperate with the follow-up.
  2. Age 18\~75 years old.
  3. or histologically confirmed diagnosis of recurrent epithelial ovarian, fallopian tube, or primary peritoneum cancer.
  4. Patient has been previously treated with a platinum-containing regimen and has been treated with a platinum-based regimen during the last dose of platinum-based therapy (self-treatment initiation to within 1 month after the last dose) efficacy is non-PD, 6 months after the end of treatment (183 disease progression or recurrence within calendar days, and the number of after platinum resistance ≤1 line.
  5. At least one per v1.1 criteria.
  6. PS score: 0-1 points.
  7. Expected survival period ≥ 3 weeks.
  8. Good level of organ function.
  9. Subjects of who need to use highly effective from the time of signing informed to 210 days after the last dose of trial drug; Subjects of childbearing potential must have a negative serum HCG within 7 days prior to the first dose and must be non-lactating.

Exclusion criteria

Exclusion Criteria:

  1. Those who have received chemotherapy, , major surgical operations, anti-tumor vaccines within 4 weeks before the first dose; Those who have received palliative radiotherapy within 2 weeks prior to the first dose; Oral molecularly targeted therapy (including other clinical trial targeted agents) 5 drug half-lives or 4 weeks (whichever is shorter) \< from the first study dose; Those who have received a within 4 weeks prior to the first dose or possibly during the study.
  2. Toxicity due to prior antineoplastic therapy has not recovered according to v5.0 grade≤ Level 1.
  3. Subject has previous or concurrent other .
  4. Subject has carcinomatous meningitis, or has untreated central nervous system .
  5. Imaging shows tumor invasion of large blood vessels or unclear demarcation from blood vessels; or the investigator judges that the patient's tumor has a high possibility of invading important blood vessels and causing fatal hemorrhage during treatment.
  6. Cancerous ascites and pleural effusion with clinical symptoms, requiring puncture and drainage; or those who have received ascites, pleural effusion drainage within 14 days before the first dose of the drug.
  7. Severe bone injury due to tumor bone metastases, including severe bone pain with poor control, pathological fractures of important sites and spinal cord that have occurred within the last 6 months or are expected to occur in the near future oppression, etc.
  8. Previous or current interstitial pneumonitis/interstitial lung disease (except for those with radiographic changes only), pneumonia requiring systemic treatment with (such as radiation pneumonitis, etc.); Current active pneumonitis or those with severe impairment of lung function confirmed by pulmonary function tests.
  9. People who are known to be allergic to bevacizumab or have had a severe allergic reaction to other monoclonal antibodies.
  10. Those with active tuberculosis; Those who have been adequately treated before the first dose and have discontinued anti-tuberculosis therapy for ≥ 3 months can be enrolled.
  11. Have hypertension that is not well controlled with antihypertensive medication (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 90 mmHg); Previous hypertensive crisis or hypertensive sex encephalopathy.
  12. Have clinical symptoms or disease of the heart that are not well controlled.
  13. Coagulation abnormalities, bleeding tendency, or those receiving thrombolytic or anticoagulant therapy are allowed to receive low-dose low-molecular-weight heparin or oral aspirin prophylactic anticoagulation therapy during the trial.
  14. NCI-CTCAE v5.0 grade ≥2 bleeding events within 4 weeks prior to the first dose, including but not limited to hemoptysis (hemoptysis in a single episode ≥2mL), vaginal bleeding, gastrointestinal bleeding, etc.
  15. Experienced arterior/venous thrombotic event within 6 months prior to the first dose.
  16. Patients with gastrointestinal perforation or fistula (except artificial fistula), urethral fistula, intra-abdominal abscess, intestinal obstruction, or those requiring parenteral nutrition within 3 months prior to the first dose.
  17. Those who are unable to swallow tablets normally, or have abnormal gastrointestinal function, which may affect drug absorption as judged by the investigator.
  18. Subjects who have had a serious infection within 1 month before the first dose, including but not limited to infectious complications requiring hospitalization, bacteremia, severe pneumonia, etc.; Subjects with any active infection requiring intravenous system therapy, or who have a progeny during the screening period, prior to the first dose 38.5°C due to unknown fever>; Those who have used antibiotics within 2 weeks before the first dose.
  19. Known history of positive (HIV) test; Known active hepatitis.
  20. Treatment with a strong inhibitor of , CYP2D6, P-gp, or BCRP, \<5 drug half-lives or 14 days from the date of first dose; Treatment with the above enzyme strong inducers was 28 days \< the first dose.
  21. As judged by the investigator, there are other factors that may affect the results of the study or cause the study to be terminated halfway, such as alcoholism, drug abuse, other serious diseases (such as severe diabetes, thyroid disease, spinal cord compression, superior vena cava syndrome, psychiatric diseases) that require concomitant treatment, serious laboratory test abnormalities, accompanied by family or social factors, which will affect the safety of the subjects.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer

    Drug: Bevacizumab; HRS-1167

Interventions

  • DrugBevacizumab; HRS-1167

    Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral

06

What researchers measure

Primary outcomes

  1. The number of subjects with dose-limiting toxicity (DLT)

    Time frame: From first dose of study treatment until the end of Cycle 1(up to 21 days)

  2. Determination of Recommended Phase II dose (RP2D)

    Time frame: From first dose of study treatment until the end of Cycle 1(up to 21 days)

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage of participants with a confirmed CR or PR according to RECIST v1.1 criteria.

    Time frame: From time of first dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)]

  2. Disease Control Rate (DCR)

    The percentage of participants who have a best objective response of confirmed CR or PR or who have SD for at least 15 weeks after start of treatment

    Time frame: From time of first dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)

  3. Duration of Response (DoR)

    The time from the date of first response until date of disease progression or death in the absence of disease progression.

    Time frame: From time of first dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)

  4. Progression free Survival (PFS)

    Progression-free survival is defined as the time from the start of treatment until the date of objective disease progression or death

    Time frame: From time of fist dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)

  5. Overall Survival (OS)

    The time until death due to any cause.

    Time frame: From time of first dose of HRS-1167 or Bevacizumab until the date of death (up to 24 months)

  6. Time To Response(TTR)

    Time from C1D1 to complete or partial response, according to RECIST v1.1 criteria.

    Time frame: From time of first dose of HRS-1167 or Bevacizumab until the date of objective disease progression or death (up to 24 months)

07

Study locations

1 of 18 sites recruiting
  • First Affiliated Hospital of University of Science and Technology of China
    Hefei, Anhui 230002, China
    Not yet recruiting
    • Ying Zhou · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Not yet recruiting
    • Lingying Wu · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
    Not yet recruiting
    • Hong Zheng · Principal investigator
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400000, China
    Not yet recruiting
    • Yu Huang · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400016, China
    Not yet recruiting
    • Junying Tang · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530022, China
    Not yet recruiting
    • He Wang · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050001, China
    Not yet recruiting
    • Hui Zhang · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150001, China
    Not yet recruiting
    • Ge Lou · Principal investigator
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, Hubei 430030, China
    Not yet recruiting
    • Qinglei Gao · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Recruiting
    • Jing Wang · Principal investigator
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110042, China
    Not yet recruiting
    • Danbo Wang · Principal investigator
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
    Not yet recruiting
    • Hualei Bu · Principal investigator
  • Shandong First Medical University Affiliated Cancer Hospital
    Jinan, Shangdong 250117, China
    Not yet recruiting
    • Liang Chen · Principal investigator
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030006, China
    Not yet recruiting
    • Hongwei Zhao · Principal investigator
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610042, China
    Not yet recruiting
    • Guonan Zhang · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300000, China
    Not yet recruiting
    • Ke Wang · Principal investigator
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650118, China
    Not yet recruiting
    • Hongying Yang · Principal investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310005, China
    Not yet recruiting
    • Tao Zhu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2025, 19 months after the start.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's planned 19 months is below that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 13, 2024
StartActual
Mar 15, 2024
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2025
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06308406
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
Mar 15, 2024
Primary completion
Oct 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Apr 11, 2024

Study contacts

Xin Xu
Contact
xin.xu@hengrui.com
0518-82342973
Yuting Wang
Contact
yuting.wang@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion